NCT00681187 - Somatuline Autogel Preference and Health Economy Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Neuroendocrine Tumour With Carcinoid Symptoms

Interventions

DRUG

lanreotide (Autogel formulation)

90 mg or 120 mg once every 28th day

Trial Locations (10)

Odense Univeristy Hospital / S-AMB, Odense

Haukeland University Hospital / Kreftafd, Bergen

S:t Olavs Hospital / Medisinsk Afd, Trondheim

Aarhus University Hospital / Medisinsk afd. V, Aarhus

University Hospital North-Norway / GastroLab, Tromsø

Sahlgrenska University Hospital / Kirurgkliniken, Gothenburg

Linköping University Hospital / Onkologen, Linköping

Karolinska University Hospital, Huddinge / GastroCentrum Medicin, Stockholm

Karolinska University Hospital, Solna / Kirurgmottagningen, Stockholm

Akademiska Hospital/ Kliniken f onkologisk endokrinologi, Uppsala